Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma
Nina Shah, Jack Aiello, David Avigan, et al.
Journal for ImmunoTherapy of Cancer (2020) Vol. 8, Iss. 2, pp. e000734-e000734
Open Access | Times Cited: 37

Showing 1-25 of 37 citing articles:

Tumor Burden Limits Bispecific Antibody Efficacy through T-cell Exhaustion Averted by Concurrent Cytotoxic Therapy
Erin W. Meermeier, Seth J. Welsh, Meaghen E. Sharik, et al.
Blood Cancer Discovery (2021) Vol. 2, Iss. 4, pp. 354-369
Open Access | Times Cited: 71
Ocular Toxicity of Belantamab Mafodotin, an Oncological Perspective of Management in Relapsed and Refractory Multiple Myeloma
Ahsan Wahab, Abdul Rafae, Kamran Mushtaq, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 63
Regulation of antigen-specific T cell infiltration and spatial architecture in multiple myeloma and premalignancy
M. Hope Robinson, Nancy Villa, David L. Jaye, et al.
Journal of Clinical Investigation (2023) Vol. 133, Iss. 15
Open Access | Times Cited: 25
Immune-Based Therapy in Triple-Negative Breast Cancer: From Molecular Biology to Clinical Practice
Francesca Carlino, Anna Diana, Antonio Piccolo, et al.
Cancers (2022) Vol. 14, Iss. 9, pp. 2102-2102
Open Access | Times Cited: 34
The immune system in multiple myeloma and precursor states: Lessons and implications for immunotherapy and interception
Madhav V. Dhodapkar
American Journal of Hematology (2022) Vol. 98, Iss. S2
Open Access | Times Cited: 30
Immune dysregulation in multiple myeloma: the current and future role of cell-based immunotherapy
Brian M. Russell, David Avigan
International Journal of Hematology (2023) Vol. 117, Iss. 5, pp. 652-659
Open Access | Times Cited: 17
Monoclonal Antibodies and Antibody Drug Conjugates in Multiple Myeloma
Jakub Radocha, Niels W.C.J. van de Donk, Katja Weisel
Cancers (2021) Vol. 13, Iss. 7, pp. 1571-1571
Open Access | Times Cited: 34
De novo abnormalities identified by fluorescence in situ hybridization during follow-up confer poor prognosis in Chinese multiple myeloma
Shumin Chen, Lu Gao, Lin Feng, et al.
Frontiers in Medicine (2025) Vol. 12
Open Access
Immune-Pathogenesis of Myeloma
Madhav V. Dhodapkar
Hematology/Oncology Clinics of North America (2024) Vol. 38, Iss. 2, pp. 281-291
Closed Access | Times Cited: 4
Management of CAR-T cell therapy in patients with multiple myeloma: a systematic review and expert consensus in Australia
P. Joy Ho, Hang Quach, M Hasib Sidiqi, et al.
Frontiers in Oncology (2025) Vol. 14
Open Access
Safety assessment of proteasome inhibitors real world adverse event analysis from the FAERS database
Jinlong Huang, Miaomiao Zhang, Jingyang Lin, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
The LncRNA RP11-301G19.1/miR-582-5p/HMGB2 axis modulates the proliferation and apoptosis of multiple myeloma cancer cells via the PI3K/AKT signalling pathway
Faming Wang, Yao Luo, Le Zhang, et al.
Cancer Gene Therapy (2021) Vol. 29, Iss. 3-4, pp. 292-303
Open Access | Times Cited: 26
Monitoring the M-protein of multiple myeloma patients treated with a combination of monoclonal antibodies: the laboratory solution to eliminate interference
Somayya Noori, Christie P.M. Verkleij, Marina Zajec, et al.
Clinical Chemistry and Laboratory Medicine (CCLM) (2021) Vol. 59, Iss. 12, pp. 1963-1971
Open Access | Times Cited: 21
Drug combinations identified by high-throughput screening promote cell cycle transition and upregulate Smad pathways in myeloma
Tyler J. Peat, Snehal Gaikwad, Wendy Dubois, et al.
Cancer Letters (2023) Vol. 568, pp. 216284-216284
Closed Access | Times Cited: 7
Serum Abnormal Metabolites for Evaluating Therapeutic Response and Prognosis of Patients With Multiple Myeloma
Yujun Wei, Jinying Wang, Fei Chen, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 10
Distinguishing Daratumumab from Endogenous Monoclonal Proteins in Serum from Multiple Myeloma Patients Using an Automated Mass Spectrometry System
David R. Barnidge, Dhananjay Sakrikar, Tadeusz Kubicki, et al.
The Journal of Applied Laboratory Medicine (2024)
Open Access | Times Cited: 1
Spatiotemporal assessment of immunogenomic heterogeneity in multiple myeloma
Maximilian Merz, Qiang Hu, Almuth Maria Anni Merz, et al.
Blood Advances (2022) Vol. 7, Iss. 5, pp. 718-733
Open Access | Times Cited: 7
HLA-E Binding Peptide as a Potential Therapeutic Candidate for High-Risk Multiple Myeloma
Ying Yang, Zhuogang Liu, Hong-Tao Wang, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 9
Advances in research on potential inhibitors of multiple myeloma
Tang Guoyuan, Shan Huang, Ji Luo, et al.
European Journal of Medicinal Chemistry (2023) Vol. 262, pp. 115875-115875
Closed Access | Times Cited: 3
Gene Expression Analysis of the Bone Marrow Microenvironment Reveals Distinct Immunotypes in Smoldering Multiple Myeloma Associated to Progression to Symptomatic Disease
Ignacio Isola, Fara Brasó‐Maristany, David F. Moreno, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 8
Role of Natural Killer T (NKT) Cells in Myeloma Biology and Therapy
Madhav V. Dhodapkar
Critical Reviews™ in Oncogenesis (2023) Vol. 29, Iss. 1, pp. 63-68
Closed Access | Times Cited: 3
Multiple myeloma: an update
Lalit Kumar, Sukesh C. Nair, SuryaPrakash Vadlamani, et al.
Journal of Current Oncology (2020) Vol. 3, Iss. 2, pp. 72-72
Closed Access | Times Cited: 8
Patient and Caregiver Experience Decision Factors in Treatment Decision Making: Results of a Systematic Literature Review of Multiple Myeloma Decision Aids
Mimi Choon-Quinones, Dirk Hose, Zoltán Kaló, et al.
Value in Health (2022) Vol. 26, Iss. 1, pp. 39-49
Open Access | Times Cited: 5
Non-Clear Cell Renal Cell Carcinoma: Molecular Pathogenesis, Innovative Modeling, and Targeted Therapeutic Approaches
Niloofar Khoshdel Rad, Maryam Vahidyeganeh, Mahsa Mohammadi, et al.
International Journal of Translational Medicine (2022) Vol. 2, Iss. 4, pp. 555-573
Open Access | Times Cited: 5
Canadian perspectives in multiple myeloma on the use of steroids in clinical practice based on patient and healthcare provider interviews
Farah McKenzie, Gabriel Gazzé, Joanne Hewitt, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top